ASX Stock of the Day: Bioxyne (ASX: BXN)
- futuregatecapital
- Feb 8
- 1 min read
QUARTERLY ACTIVITIES REPORT FOR THE PERIOD ENDED 31 DECEMBER 2024
Highlights
Q2 Revenue: $8.1M, up 77% on Q1 and 310% YoY growth from Q2 FY24.
H1 FY25 Revenue: $12.6M, marking a 267% increase from the previous half.
Positive Operating Cash Flow: $1.5M for the quarter from $7.4M in cash receipts.
Cash Reserves: $2.7M as of 31 December 2024.
Manufacturing Expansion: Increased capacity set for commissioning in February 2025 to support rising production demand.
Regulatory Approvals: Expected soon for UK export clearance.
Future Growth Plans: Planning underway for a proposed GMP manufacturing facility in Europe to meet regional demand.
Financial Performance
Positive Cash Flow: $1.2M in Q1 FY25, a strong turnaround from the $759K loss in Q4 FY24.
Strong Cash Receipts: $5.8M in Q1 FY25, up 117% from $2.65M in Q4 FY24.
FY24 Revenue: $9.66M
FY25 Target: $20M+, a projected 107% YoY growth.
Profitability & Market Position
Gross Profit Margin: 36% in FY24, up from 28% in FY23.
Cash on Hand: $2.7M (as of Q2 FY25).
Market Capitalization (MC): $51M SP $0.25
Comments